摘要：Despite growing prevalence of ovarian cancer (OC) in Pakistan,no literature evidence exists regarding its clinic- -pathological characteristics,survival and compliance of patients with recurrent ovarian cancer on various chemo- -protocols.An observational study was conducted by enrolling 251 recurrent OC patients on 7 different chemo- -protocols,from a specialized cancer care hospital,Lahore,Pakistan,using convenient judgmental sampling.The study was conducted for a period of 6 months.Most of the patients were between 18 and 70 years of age,with IIIC FIGO stage and papillary serous histological grade.As per RECIST,improved partial response (PR) (63.3 %) and complete response (CR) (52.1 %) was observed in the CP (carboplatin + paclitaxel) arm,substantiated by improved median progression free survival (PFS) and overall survival (OS) in CP and CD (carboplatin + docetaxel) arms,respectively,yet with no significant differences in survival curves,PFS (p = 0.12) and OS (p = 0.22).Interestingly,the highest and the lowest patient non-compliance were observed in CG (carboplatin + gemcitabine) (81.6 %) and paclitaxel (4.5 %) arms,resp.As per the hazard model for survival,topotecan showed significant association with the therapy related events/deaths compared to other protocols.These data suggest that CP regimen exhibited improved clinical efficacy and decreased toxicity related non-compliance in recurrent ovarian cancer patients of Lahore.
关键词：ovarian cancer;carboplatin plus paclitaxel;topotecan;bevacizumab;docetaxel
